



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



ALFONSO DUEÑAS GONZALEZ

Datos Generales

Nombre: ALFONSO DUEÑAS GONZALEZ

Máximo nivel de estudios: DOCTORADO

Antigüedad académica en la UNAM: 24 años

Nombramientos

Último: INVESTIGADOR TITULAR C TC Definitivo
Instituto de Investigaciones Biomédicas
Desde 16-10-2009 hasta 15-01-2025


Estímulos, programas, premios y reconocimientos

SNI III 2010 - 2024
SNI II - 2009
PRIDE D - 2024
PUN Innovación tecnológica y diseño industrial 2012

ALFONSO DUEÑAS GONZALEZ

DOCUMENTOS EN REVISTAS

Histórico de Documentos



#	Título	Autores	Revista	Año
1	Concurrent Genomic Alterations on Clinical Outcomes in Patients With Alk-rearranged NSCLC	ALFONSO DUEÑAS GONZALEZ Bornstein-Quevedo L.	JOURNAL OF THORACIC ONCOLOGY	2025
2	Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	ALFONSO DUEÑAS GONZALEZ Aurora Gonzalez-Fierro Guadalupe Dominguez-Gomez et al.	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2025
3	Increased amounts of cell-free DNA released from a culture with a high content of cancer stem cells	TALIA WEGMAN OSTROSKY ALEJANDRO ZENTELLA DEHESA ALFONSO DUEÑAS GONZALEZ et al.	Frontiers In Cell And Developmental Biology	2025
4	The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer	JUAN PABLO REYES GRAJEDA MARCO ANTONIO VELASCO VELAZQUEZ ALFONSO DUEÑAS GONZALEZ et al.	MOLECULAR BIOLOGY REPORTS	2024
5	Selection of clinically relevant drug concentrations for in vitro studies of candidates drugs for cancer repurposing: a proposal	ADRIANA ROMO PEREZ ALFONSO DUEÑAS GONZALEZ Benjamin Robles-Banuelos et al.	CLINICAL & TRANSLATIONAL ONCOLOGY	2024
6	PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal	ADRIANA ROMO PEREZ ALFONSO DUEÑAS GONZALEZ Dominguez-Gomez G. et al.	CURRENT MEDICINAL CHEMISTRY	2024

ALFONSO DUEÑAS GONZALEZ

7	Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ ADRIANA ROMO PEREZ et al.	EXPERT REVIEW OF ANTICANCER THERAPY	2024
8	N-(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression	ALFONSO DUEÑAS GONZALEZ SELMA ALIN SOMILLED A VENTURA Prestegui Martel B. et al.	Molecules	2024
9	Combinational therapies for the treatment of advanced cervical cancer	ALFONSO DUEÑAS GONZALEZ	EXPERT OPINION ON PHARMACOTHERAPY	2023
10	Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?	ADRIANA ROMO PEREZ ALFONSO DUEÑAS GONZALEZ Aurora Gonzalez-Fierro et al.	CLINICAL DRUG INVESTIGATION	2023
11	Data presentation of results from randomized cancer clinical trials. The case for trials in advanced cervical cancer. A critical appraisal.	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ Coronel J. et al.	F1000 Research	2023
12	Hereditary diffuse gastric cancer (HDGC). An overview	ALFONSO DUEÑAS GONZALEZ Taja-Chayeb L. Vidal-Millán S. et al.	CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY	2022
13	BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal	ADRIANA ROMO PEREZ ALFONSO DUEÑAS GONZALEZ Dominguez-Gomez G. et al.	Current Molecular Pharmacology	2022
14	Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications	ADRIANA ROMO PEREZ ALFONSO DUEÑAS GONZALEZ Dominguez-Gomez G. et al.	CURRENT CANCER DRUG TARGETS	2022
15	The health system and access to treatment in patients with cervical cancer in Mexico	MARIA DE LOS DOLORES GALLARDO RINCON IVETTE CRUZ BAUTISTA ALFONSO DUEÑAS GONZALEZ et al.	Frontiers in Oncology	2022
16	Mouse Model for Efficient Simultaneous Targeting of Glycolysis, Glutaminolysis, and De Novo Synthesis of Fatty Acids in Colon Cancer	ALFONSO DUEÑAS GONZALEZ Schcolnik-Cabrera A.	Methods in Molecular Biology	2021
17	Modifications on the tetrahydroquinoline scaffold targeting a phenylalanine cluster on GPER as antiproliferative compounds against renal, liver and pancreatic cancer cells	ALFONSO DUEÑAS GONZALEZ Méndez-Luna D. Morelos-Garnica L.A. et al.	Pharmaceutica ls	2021

ALFONSO DUEÑAS GONZALEZ

18	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ	Therapeutic Advances in Hematology	2021
19	Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy	ARIANA ELIZABETH VARGAS CASTILLO ARMANDO ROBERTO TOVAR PALACIO JOSE DE LA LUZ DIAZ CHAVEZ et al.	SCIENTIFIC REPORTS	2021
20	Perspectives on Drug Repurposing	ALFONSO DUEÑAS GONZALEZ Alejandro Schcolnik-Cabrera Daniel Juarez-Lopez	CURRENT MEDICINAL CHEMISTRY	2021
21	The role of extracellular DNA (exDNA) in cellular processes	Joaquin Manzo Merino ALFONSO DUEÑAS GONZALEZ ZEFERINO ENRIQUE PEREZ CARDENAS et al.	CANCER BIOLOGY & THERAPY	2021
22	LATE-ONSET HEMATOLOGICAL TOXICITY (LOHT) IN PATIENTS WITH B-CELL LYMPHOMAS: A SURVEY IN 758 CASES	ALFONSO DUEÑAS GONZALEZ Adriana Palacios-Campos Olga Gutierrez-Hernandez et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2021
23	A COHORT STUDY OF THE PROGNOSTIC IMPACT OF EXON-16 EZH2 MUTATIONS IN A MEXICAN-MESTIZO POPULATION OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	ALEJANDRO AVILES SALAS DAVID FRANCISCO CANTU DE LEON ALFONSO DUEÑAS GONZALEZ et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2021
24	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico	ALFONSO DUEÑAS GONZALEZ Gonzalez-Fierro A.	THERAPEUTIC INNOVATION & REGULATORY SCIENCE	2020
25	In Vitro Employment of Recombinant Taenia solium Calreticulin as a Novel Strategy Against Breast and Ovarian Cancer Stem-like Cells	MAYRA YOLANDA CRUZ RIVERA ANA FLISSER STEINBRUCH ALFONSO DUEÑAS GONZALEZ et al.	Archives Of Medical Research	2020
26	Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug	ALFONSO DUEÑAS GONZALEZ Mandy Juarez Alejandro Schcolnik-Cabrera et al.	CANCER CHEMOTHERAPY AND PHARMACOLOG Y	2020
27	The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells	ARMANDO ROBERTO TOVAR PALACIO JOSE DE LA LUZ DIAZ CHAVEZ ALFONSO DUEÑAS GONZALEZ et al.	ONCOLOGY LETTERS	2020

ALFONSO DUEÑAS GONZALEZ

28	Targeting breast cancer cells with g4 pamam dendrimers and valproic acid derivative complexes	ALFONSO DUEÑAS GONZALEZ MARTINIANO BELLO RAMIREZ Muñoz A.M. et al.	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY	2020
29	IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER	LEONARDO SAUL LINO SILVA ALFONSO DUEÑAS GONZALEZ Jiménez-Lima R. et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2020
30	Investigation of HER-2 status, treatment response and survival analysis in cervical cancer patients	ZEFERINO ENRIQUE PEREZ CARDENAS ALFONSO DUEÑAS GONZALEZ Lucia Taja-Chayeb et al.	EUROPEAN JOURNAL OF GYNAECOLOGIC AL ONCOLOGY	2020
31	Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico	ALFONSO DUEÑAS GONZALEZ Gonzalez-Fierro A.	THERAPEUTIC INNOVATION & REGULATORY SCIENCE	2019
32	Growth inhibition and transcriptional effects of ribavirin in lymphoma	JOSE DE LA LUZ DIAZ CHAVEZ ALFONSO DUEÑAS GONZALEZ Dominguez-Gomez G. et al.	ONCOLOGY REPORTS	2019
33	Pharmacodynamics of current and emerging treatments for cervical cancer	ALFONSO DUEÑAS GONZALEZ Aurora Gonzalez-Fierro	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2019
34	A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells	ALFONSO DUEÑAS GONZALEZ Schcolnik-Cabrera A. Dominguez-Gómez G. et al.	ONCOLOGY LETTERS	2019
35	Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects	ALFONSO DUEÑAS GONZALEZ Gonzalez-Fierro A.	Expert Review Of Precision Medicine And Drug Development	2019
36	Ivermectin as an inhibitor of cancer stem-like cells	JOSE LUIS MEDINA FRANCO ALFONSO DUEÑAS GONZALEZ FERNANDA ISABEL SALDIVAR GONZALEZ et al.	MOLECULAR MEDICINE REPORTS	2018
37	The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug	ALFONSO DUEÑAS GONZALEZ Mandy Juarez Alejandro Schcolnik-Cabrera	AMERICAN JOURNAL OF CANCER RESEARCH	2018

ALFONSO DUEÑAS GONZALEZ

38	Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy	ALFONSO DUEÑAS GONZALEZ Alejandro Schcolnik-Cabrera Alma Chavez-Blanco et al.	EXPERT OPINION ON INVESTIGATIONAL DRUGS	2018
39	Cytotoxic Activity and Structure?Activity Relationship of Triazole-Containing Bis(Aryl Ether) Macrocycles	EDUARDO HERNANDEZ VAZQUEZ ALEJANDRA CHAVEZ RIVEROS MARIA TERESA OBDULIA RAMIREZ APAN et al.	Chemmedchem	2018
40	Advancing clinical research globally: Cervical cancer research network from Mexico	MARIA DE LOS DOLORES GALLARDO RINCON DAVID FRANCISCO CANTU DE LEON ALFONSO DUEÑAS GONZALEZ et al.	Gynecologic Oncology Reports	2018
41	Metabolic tumor volume changes assessed by interval (18)fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ Oñate-Ocaña L.F. et al.	ONCOLOGY LETTERS	2018
42	Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine in cutaneous t-cell lymphoma in HUT78 cells	ALFONSO DUEÑAS GONZALEZ Alejandro Schcolnik-Cabrera Guadalupe Dominguez-Gomez	American Journal of Blood Research	2018
43	Epidemiological data on the nutritional status of cancer patients receiving treatment with concomitant chemoradiotherapy, radiotherapy or sequential chemoradiotherapy to the abdominopelvic area	AURORA ELIZABETH SERRALDE ZUÑIGA JOSE LUIS AGUILAR PONCE SAMUEL RIVERA RIVERA et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2018
44	Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells	ELIZABETH LANGLEY MCCARRON ALEJANDRO MANUEL GARCIA CARRANCA ALFONSO DUEÑAS GONZALEZ et al.	ONCOTARGETS AND THERAPY	2018
45	Carboplatin and low-dose paclitaxel. An effective regimen in older and comorbid patients with advanced cervical cancer. A phase II study	ALFONSO DUEÑAS GONZALEZ J. Coronel D. Cantu et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2018

ALFONSO DUEÑAS GONZALEZ

46	Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand	ALFONSO DUEÑAS GONZALEZ M. Martínez-Archundia J. B. García-Vazquez et al.	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY	2018
47	Ultrasound, histopathological, and genetic features of uveal melanoma in a Mexican-Mestizo population	ABELARDO ANTONIO RODRIGUEZ REYES ALFONSO DUEÑAS GONZALEZ Delgado S. et al.	Archivos de la Sociedad Española de Oftalmología	2018
48	Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells	ALFONSO DUEÑAS GONZALEZ Martínez-Muñoz A. Prestegui-Martel B. et al.	ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY	2018
49	Evaluation of ivermectin as an antitumoural drug	ALFONSO DUEÑAS GONZALEZ Mandy Juárez Alma Chavez	CLINICAL & EXPERIMENTAL METASTASIS	2017
50	Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using Isonidamide, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer	ALFONSO DUEÑAS GONZALEZ Cervantes-Madrid, D. Dominguez-Gomez, G. et al.	ONCOLOGY LETTERS	2017
51	Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study	JUAN RAFAEL LABARDINI MENDEZ MYRNA GLORIA CANDELARIA HERNANDEZ VALENTIN LOZANO ZAVALETA et al.	EXPERT OPINION ON INVESTIGATIONAL DRUGS	2017
52	Encouraging results with the compassionate use of hydralazine/valproate (TRANSCRIPTION) as epigenetic treatment for myelodysplastic syndrome (MDS)	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Burgos, Sebastian et al.	ANNALS OF HEMATOLOGY	2017
53	Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region	ALFONSO DUEÑAS GONZALEZ Martínez-Mesa, J. Werutsky, G. et al.	Public Health	2017
54	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia	ALFONSO DUEÑAS GONZALEZ Scholnik-Cabrera, Alejandro Chavez-Blanco, Alma et al.	AMERICAN JOURNAL OF CANCER RESEARCH	2017

ALFONSO DUEÑAS GONZALEZ

55	The safety of drug treatments for cervical cancer	ALFONSO DUEÑAS GONZALEZ Cetina, Lucely Coronel, Jaime et al.	EXPERT OPINION ON DRUG SAFETY	2016
56	Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers	ALFONSO DUEÑAS GONZALEZ JOSE LUIS MEDINA FRANCO ELI ANTONIO ALONSO FERNANDEZ DE GORTARI et al.	EXPERT OPINION ON PHARMACOTHERAPY	2016
57	Hydralazine-valproate: A repositioned drug combination for the epigenetic therapy of cancer	ALFONSO DUEÑAS GONZALEZ	TOXICOLOGY LETTERS	2016
58	Clinical presentation and management of uveal melanoma (Review)	ALFONSO DUEÑAS GONZALEZ Abelardo Rodriguez Sarai Delgado-Pelayo	Molecular and Clinical Oncology	2016
59	Antitumor Effects of Systemic DNase I and Proteases in an In Vivo Model	ALFONSO DUEÑAS GONZALEZ Trejo-Becerril, Catalina Perez-Cardenas, Enrique et al.	INTEGRATIVE CANCER THERAPIES	2016
60	Viral inhibitors of NKG2D ligands for tumor surveillance	ALFONSO DUEÑAS GONZALEZ Chavez-Blanco, Alma Chacon-Salinas, Rommel et al.	EXPERT OPINION ON THERAPEUTIC TARGETS	2016
61	G80A SINGLE NUCLEOTIDE POLYMORPHISM IN REDUCED FOLATE CARRIER-1 GENE IN A MEXICAN POPULATION AND ITS IMPACT ON SURVIVAL IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA	MYRNA GLORIA CANDELARIA HERNANDEZ JUAN SALVADOR OJEDA SANTANA ALFONSO DUEÑAS GONZALEZ et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2016
62	Global strategies for the treatment of early-stage and advanced cervical cancer	ALFONSO DUEÑAS GONZALEZ Campbell, Sergio	CURRENT OPINION IN OBSTETRICS & GYNECOLOGY	2016
63	N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells	ALFONSO DUEÑAS GONZALEZ Prestegui-Martel, Berenice Antonio Bermudez-Lugo, Jorge et al.	JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY	2016
64	Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin	G. DominguezGomez J. DiazChavez A. ChavezBlanco et al.	ONCOLOGY REPORTS	2015
65	Ribavirin as a tri-targeted antitumor repositioned drug	JOSE LUIS MEDINA FRANCO ALFONSO DUEÑAS GONZALEZ De La CruzHernandez, Erick et al.	ONCOLOGY REPORTS	2015

ALFONSO DUEÑAS GONZALEZ

66	Therapy-related myelodysplastic syndrome	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ	EXPERT OPINION ON DRUG SAFETY	2015
67	A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer	ALFONSO DUEÑAS GONZALEZ Cetina, Lucely Crombet, Tania et al.	CANCER BIOLOGY & THERAPY	2015
68	Discovery and development of DNA methyltransferase inhibitors using in silico approaches This paper is dedicated to the memory of Dr Eugene Athanas Bratoeff Titeff honoring his many contributions to drug discovery.	JOSE LUIS MEDINA FRANCO OSCAR MENDEZ LUCIO ALFONSO DUEÑAS GONZALEZ et al.	DRUG DISCOVERY TODAY	2015
69	Emerging drugs for the treatment of cervical cancer	ALFONSO DUEÑAS GONZALEZ SerranoOlvera, Alberto Cetina, Lucely et al.	EXPERT OPINION ON EMERGING DRUGS	2015
70	Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids	Diana CervantesMadrid ALFONSO DUEÑAS GONZALEZ	ONCOLOGY REPORTS	2015
71	Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy	Yair Romero ALFONSO DUEÑAS GONZALEZ CervantesMadrid, Diana	BIOMED RESEARCH INTERNATIONAL	2015
72	Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin	Guadalupe DominguezGomez Alma ChavezBlanco Jose DiazChavez et al.	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE	2015
73	Follow-up consultations for cervical cancer patients in a Mexican cancer center. Comparison with NCCN guidelines	Alberto Serrano Olvera Lucely Cetina Jaime Coronel et al.	ASIAN PACIFIC JOURNAL OF CANCER PREVENTION	2014
74	New pharmacotherapy options for cervical cancer	ALFONSO DUEÑAS GONZALEZ Cetina, Lucely Coronel, Jaime et al.	EXPERT OPINION ON PHARMACOTHE RAPY	2014
75	The impact of DNA methylation technologies on drug toxicology	ALFONSO DUEÑAS GONZALEZ Brenda Alatorre Aurora Gonzalez Fierro	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2014

ALFONSO DUEÑAS GONZALEZ

76	Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure	ALFONSO DUEÑAS GONZALEZ Garces-Eisele, S. J. Cedillo-Carvalho, B. et al.	Journal Of Clinical Pharmacy And Therapeutics	2014
77	Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate	E. Mani LUIS ALBERTO MEDINA VELAZQUEZ ALFONSO DUEÑAS GONZALEZ et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2014
78	Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer	ALFONSO DUEÑAS GONZALEZ Jaime Coronel Lucely Cetina et al.	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2014
79	In Vivo Rat Model to Study Horizontal Tumor Progression	ALFONSO DUEÑAS GONZALEZ Trejo-Becerril C. Pérez-Cárdenas E.	Methods in Molecular Biology	2014
80	New molecular targets against cervical cancer	ALFONSO DUEÑAS GONZALEZ Serrano-Olvera A. Cetina L. et al.	INTERNATIONAL JOURNAL OF WOMENS HEALTH	2014
81	Relación entre niveles de CA-125 y características clínicas e histopatológicas en el cáncer epitelial de ovario	ALFONSO DUEÑAS GONZALEZ Dolores-Velázquez R. Bustamante-Montes L.P. et al.	GACETA MEXICANA DE ONCOLOGIA	2014
82	Planning cancer control in Latin America and the Caribbean	ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ Goss, Paul E. et al.	LANCET ONCOLOGY	2013
83	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for	ALFONSO DUEÑAS GONZALEZ Kast, Richard E. Boockvar, John A. et al.	Oncotarget	2013
84	Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: A randomized, phase III study in IB2-IIB cervical cancer patients	ALFONSO DUEÑAS GONZALEZ Cetina, L. Gonzalez-Enciso, A. et al.	ANNALS OF ONCOLOGY	2013
85	A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients	Jaime Alberto Coronel Lucely del Carmen Cetina DAVID FRANCISCO CANTU DE LEON et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2013
86	Dna methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells	ALFONSO DUEÑAS GONZALEZ Candelaria, Myrna de la Cruz-Hernandez, Erick et al.	PLOS ONE	2012

ALFONSO DUEÑAS GONZALEZ

87	Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia	ALFONSO DUEÑAS GONZALEZ Cervera, Eduardo Candelaria, Myrna et al.	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2012
88	Arylamine N-acetyltransferase 2 genotypes in a Mexican population	ALFONSO DUEÑAS GONZALEZ Taja-Chayeb, L. Agundez, J. A. et al.	GENETICS AND MOLECULAR RESEARCH	2012
89	Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chernoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and pre	ALFONSO DUEÑAS GONZALEZ Orlando, M. Zhou, Y. et al.	GYNECOLOGIC ONCOLOGY	2012
90	Late recurrence of cervical cancer: a report of 16 cases	ALFONSO DUEÑAS GONZALEZ Cetina, L. Garcia-Arias, A. et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2012
91	Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model	LUIS ALBERTO MEDINA VELAZQUEZ ALFONSO DUEÑAS GONZALEZ Trejo-Becerril, Catalina et al.	PLOS ONE	2012
92	An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers	ALFONSO DUEÑAS GONZALEZ Pinto, E. M. Ribeiro, R. C. et al.	ONCOGENESIS	2012
93	Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial	ALFONSO DUEÑAS GONZALEZ Candelaria, Myrna Herrera, Aquileo et al.	ANNALS OF HEMATOLOGY	2011
94	F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma	Martha Hernandez Lucio ALFONSO DUEÑAS GONZALEZ Cetina, Lucely et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2011
95	Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetyla	A. Gonzalez Fierro D. Vasquez Bahena L. Taja Chayeb et al.	INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS	2011

ALFONSO DUEÑAS GONZALEZ

96	Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate	MARIA GUADALUPE DOMINGUEZ MACOUZET ALFONSO DUEÑAS GONZALEZ Chavez-Blanco, A. et al.	INTERNATIONAL JOURNAL OF ONCOLOGY	2011
97	Acetylator status and N-acetyltransferase 2 gene polymorphisms; Phenotype-genotype correlation with the sulfamethazine test	Lucia Taja Chayeb Aurora Gonzalez Fierro Cristian Miguez Munoz et al.	PHARMACOGENETICS AND GENOMICS	2011
98	Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer	ALFONSO DUEÑAS GONZALEZ Coronel, J Cetina, L	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2011
99	Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer	MARTHA PATRICIA OSTROSKY SHEJET ALFONSO DUEÑAS GONZALEZ DULCE MARIA HERNANDEZ HERNANDEZ et al.	MEDICAL ONCOLOGY	2011
100	A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary result	ALFONSO DUEÑAS GONZALEZ Coronel, Jaime Cetina, Lucely et al.	MEDICAL ONCOLOGY	2011
101	The place of topotecan and other drugs in the management of advanced/relapsed cervix cancer	ALFONSO DUEÑAS GONZALEZ Coronel J. Cetina L.	European journal of Clinical and Medical Oncology	2011
102	Randomized, double blind, phase II trial: Epigenetic therapy (valproic acid and hydralazine) plus chemotherapy versus placebo plus neoadjuvant chemotherapy in operable and local	C. Arce ALFONSO DUEÑAS GONZALEZ ALEJANDRO MOHAR BETANCOURT et al.	JOURNAL OF CLINICAL ONCOLOGY	2011
103	Primer consenso Mexicano de cáncer de endometrio: Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"	EUCARIO LEON RODRIGUEZ ALFONSO DUEÑAS GONZALEZ RAMIRO JESUS SANDOVAL et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2010
104	[The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México]. [Primer consenso Mexicano de cancer de endometrio.]	EUCARIO LEON RODRIGUEZ ALFONSO DUEÑAS GONZALEZ RAMIRO JESUS SANDOVAL et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2010

ALFONSO DUEÑAS GONZALEZ

105	Pharmacotherapy Options for Locally Advanced and Advanced Cervical Cancer	ALFONSO DUEÑAS GONZALEZ Cetina, Lucely Coronel, Jaime et al.	Drugs	2010
106	Epigenetic therapy and cisplatin chemoradiation in FIGO Stage IIIB cervical cancer	ALFONSO DUEÑAS GONZALEZ Candelaria, M. Cetina, L. et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2010
107	Pharmacogenetics and pharmacoeugenetics of gemcitabine	ALFONSO DUEÑAS GONZALEZ Candelaria, M. de la Cruz-Hernandez, E. et al.	MEDICAL ONCOLOGY	2010
108	Epigenetic changes in nucleoside transporter hENT1 and dCK, as mechanism for gemcitabine-acquired resistance in cervical cancer cell lines.	MYRNA GLORIA CANDELARIA HERNANDEZ E. de la Cruz Hernandez A. Gonzalez Fierro et al.	JOURNAL OF CLINICAL ONCOLOGY	2010
109	Response to hydralazine-valproate in a patient with mycosis fungoides	ALFONSO DUEÑAS GONZALEZ DEBORAH MARIA MARTINEZ BAÑOS LINDA GARCIA HIDALGO et al.	Case Reports In Medicine	2010
110	E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway	Adriana Contreras Paredes Erick de la Cruz Hernandez Imelda Martinez Ramirez et al.	Virology	2009
111	Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIIB cervical cancer patients	DAVID FRANCISCO CANTU DE LEON AARON GONZALEZ ENCISO ALFONSO DUEÑAS GONZALEZ et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2009
112	Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer	ALFONSO DUEÑAS GONZALEZ Coronel, Jaime Cetina, Lucely et al.	MEDICAL ONCOLOGY	2009
113	Molecular Modeling and Molecular Dynamics Studies of Hydralazine with Human DNA Methyltransferase 1	ALFONSO DUEÑAS GONZALEZ Singh, Narender Lyko, Frank et al.	Chemmedchem	2009
114	Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients	ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ Vidal-Millan, S. et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2009
115	Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor a	MYRNA GLORIA CANDELARIA HERNANDEZ Daymi Arias Bonfill Alma Chavez Blanco et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2009

ALFONSO DUEÑAS GONZALEZ

116	Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome	ALFONSO DUEÑAS GONZALEZ Taja-Chayeb, Lucia Vidal-Millan, Silvia et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2009
117	Thiopurine S-methyltransferase Gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients	Patricia Ostrosky Wegman ALFONSO DUEÑAS GONZALEZ Taja-Chayeb, Lucia et al.	MEDICAL ONCOLOGY	2008
118	The epigenetic origin of aneuploidy	LUIS ALONSO HERRERA MONTALVO DIDIER GIOVANNI PRADA ORTEGA MARCO ALONSO ANDONEGUI ELGUERA et al.	CURRENT GENOMICS	2008
119	Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ CARLOS GUADALUPE PEREZ PLASENCIA et al.	CANCER TREAT REV	2008
120	Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer	L. Cetina A. Garcia Arias M. de Jesus Uribe et al.	EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	2008
121	The prince and the pauper. A tale of anticancer targeted agents	ALFONSO DUEÑAS GONZALEZ PATRICIA GARCIA LOPEZ LUIS ALONSO HERRERA MONTALVO et al.	MOLECULAR CANCER	2008
122	Activación de la vía de Wnt/beta catenina en el proceso de carcinogenesis cervical	CARLOS GUADALUPE PEREZ PLASENCIA ALFONSO DUEÑAS GONZALEZ Bustos-Martínez J.	Archivos de Medicina	2008
123	Primary retroperitoneal mucinous cystadenocarcinoma: report of two cases.	DAVID FRANCISCO CANTU DE LEON JOSE GREGORIO CHANONA VILCHIS ALFONSO DUEÑAS GONZALEZ et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2007
124	The prognostic significance of leukocytosis in cervical cancer	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Garcia-Arias A. et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2007
125	Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico	ROBERTO EDUARDO HERRERA GOEPFERT ALFONSO DUEÑAS GONZALEZ Oñate-Ocaña L.F. et al.	ANNALS OF SURGICAL ONCOLOGY	2007
126	A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors	MYRNA GLORIA CANDELARIA HERNANDEZ OSCAR GERARDO ARRIETA RODRIGUEZ CARLOS GUADALUPE PEREZ PLASENCIA et al.	ANNALS OF ONCOLOGY	2007

ALFONSO DUEÑAS GONZALEZ

127	Primary retroperitoneal mucinous cystadenocarcinoma: Report of two cases	DAVID FRANCISCO CANTU DE LEON JOSE GREGORIO CHANONA VILCHIS ALFONSO DUEÑAS GONZALEZ et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2007
128	Tamoxifen-associated vasculitis in a breast cancer patient	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Hurtado-Monroy R. et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2007
129	The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study	DAVID FRANCISCO CANTU DE LEON ALEJANDRO MOHAR BETANCOURT MARCELA LIZANO SOBERON et al.	VIROLOGY JOURNAL	2007
130	A proof-of-principle study of epigenetics therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer	ALMA LUISA REVILLA VAZQUEZ MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ et al.	PLOS ONE	2006
131	Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid	ALFONSO DUEÑAS GONZALEZ JORGE HERNANDEZ MONTES BENNY WEISS STEIDER et al.	JOURNAL OF TRANSLATIONAL MEDICINE	2006
132	Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population	MARCELA LIZANO SOBERON ALEJANDRO MANUEL GARCIA CARRANCA ALFONSO DUEÑAS GONZALEZ et al.	GYNECOLOGIC ONCOLOGY	2006
133	Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?	CARLOS GUADALUPE PEREZ PLASENCIA ALFONSO DUEÑAS GONZALEZ	MOLECULAR CANCER	2006
134	Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine	ALMA LUISA REVILLA VAZQUEZ LUIS SOTERO BENITEZ Y BRIBIESCA ALFONSO DUEÑAS GONZALEZ et al.	JOURNAL OF TRANSLATIONAL MEDICINE	2006
135	Radiosensitizers in cervical cancer. Cisplatin and beyond	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Garcia-Arias A. et al.	RADIAT ONCOL	2006
136	A novel one pot, solvent-free Mannich synthesis of methylpiperidinyl phenols, methylphenylmorpholinyl phenols and methylthiophenylmorpholinyl phenols using infrared light irradiation	ANA MARIA VELAZQUEZ SANCHEZ LUIS ALBERTO TORRES ANDRADE ALBERTO RAMIREZ PIEDRABUENA et al.	Arkivoc	2006

ALFONSO DUEÑAS GONZALEZ

137	Prognostic significance of pathological response after neoadjuvant chemotherapy of chemoradiation for locally advanced cervical carcinoma	MYRNA GLORIA CANDELARIA HERNANDEZ JOSE GREGORIO CHANONA VILCHIS DAVID FRANCISCO CANTU DE LEON et al.	International Seminars in Surgical Oncology	2006
138	Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results	DAVID FRANCISCO CANTU DE LEON MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ et al.	BMC Womens Health	2006
139	Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines	CARLOS GUADALUPE PEREZ PLASENCIA MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ et al.	CANCER CELL INTERNATIONAL	2006
140	Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ Serrano-Olvera A. et al.	CANCER TREAT REV	2006
141	Genetic determinants of cancer drug efficacy and toxicity: Practical considerations and perspectives	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Taja-Chayeb L. et al.	ANTI-CANCER DRUGS	2005
142	Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: Case report and review of the literature	ALFONSO DUEÑAS GONZALEZ Arce C. Cortes-Padilla D. et al.	WORLD JOURNAL OF SURGICAL ONCOLOGY	2005
143	Epigenetics of cervical cancer. An overview and therapeutic perspectives	ALFONSO DUEÑAS GONZALEZ MARCELA LIZANO SOBERON MYRNA GLORIA CANDELARIA HERNANDEZ et al.	MOLECULAR CANCER	2005
144	Determination of 5-methyl-cytosine and cytosine in tumor DNA of cancer patients	ALFONSO DUEÑAS GONZALEZ Sandoval Guerrero K. Revilla Vázquez A. et al.	Electrophoresis	2005
145	A clinical and biological overview of gastrointestinal stromal tumors	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ De La Garza J.	MEDICAL ONCOLOGY	2005
146	Computational studies of 1-hydrazinophthalazine (hydralazine) as an antineoplastic agent. Docking studies on methyltransferase	ENRIQUE RAMON ANGELES ANGUIANO VICTOR HUGO VAZQUEZ VALADEZ ANA MARIA VELAZQUEZ SANCHEZ et al.	LETTERS IN DRUG DESIGN & DISCOVERY	2005
147	Anemia in cervical cancer patients: Implications for iron supplementation therapy	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Cetina L.	MEDICAL ONCOLOGY	2005
148	Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences	ALEJANDRO MANUEL GARCIA CARRANCA ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ et al.	JOURNAL OF GENERAL VIROLOGY	2005

ALFONSO DUEÑAS GONZALEZ

149	Overexpression of cathepsin f, matrix metalloproteinases 11 and 12 in cervical cancer	ALFONSO DUEÑAS GONZALEZ Vazquez-Ortiz G. Pina-Sanchez P. et al.	Bmc Cancer	2005
150	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Taja-Chayeb L. et al.	LUNG CANCER	2005
151	Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer	AARON GONZALEZ ENCISO DAVID FRANCISCO CANTU DE LEON MYRNA GLORIA CANDELARIA HERNANDEZ et al.	Bmc Cancer	2005
152	A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes	ALMA LUISA REVILLA VAZQUEZ ENRIQUE RAMON ANGELES ANGUIANO JOSE GREGORIO CHANONA VILCHIS et al.	Bmc Cancer	2005
153	Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study	MYRNA GLORIA CANDELARIA HERNANDEZ DAVID FRANCISCO CANTU DE LEON PATRICIA GARCIA LOPEZ et al.	MOLECULAR CANCER	2005
154	Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance	AMERICA VANOYE CARLO ALFONSO DUEÑAS GONZALEZ Trejo-Becerril C. et al.	Bmc Cancer	2005
155	Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: A randomized Phase II study	ALFONSO DUEÑAS GONZALEZ ALEJANDRO MOHAR BETANCOURT Cetina-Perez L. et al.	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS	2005
156	Erratum: Overexpression of cathepsin f, matrix metalloproteinases 11 and 12 in cervical cancer (BMC Cancer)	ALFONSO DUEÑAS GONZALEZ PATRICIA MENDOZA LORENZO Vázquez-Ortiz G. et al.	Bmc Cancer	2005
157	Ocular metastases from breast carcinoma	ALFONSO DUEÑAS GONZALEZ MYRNA GLORIA CANDELARIA HERNANDEZ Mejía-Novelo A. et al.	MEDICAL ONCOLOGY	2004
158	Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck	ALFONSO DUEÑAS GONZALEZ ANGEL HERRERA GOMEZ KUAUHYAMA LUNA ORTIZ et al.	ANNALS OF ONCOLOGY	2004
159	Chemoradiation with gemcitabine for cervical cancer in patients with renal failure	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Cetina L. et al.	ANTI-CANCER DRUGS	2004

ALFONSO DUEÑAS GONZALEZ

160	Ether à go-go potassium channels as human cervical cancer markers	IGNACIO CAMACHO ARROYO ALFONSO DUEÑAS GONZALEZ Farias L.M.B. et al.	CANCER RESEARCH	2004
161	HER2 expression in cervical cancer as a potential therapeutic target	MYRNA GLORIA CANDELARIA HERNANDEZ ALFONSO DUEÑAS GONZALEZ Chavez-Blanco A. et al.	Bmc Cancer	2004
162	Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy	IGNACIO DANIEL MARISCAL MARTINEZ MARCELA LIZANO SOBERON ALFONSO DUEÑAS GONZALEZ et al.	CLINICAL CANCER RESEARCH	2003
163	Modern management of locally advanced cervical carcinoma	ALFONSO DUEÑAS GONZALEZ IGNACIO DANIEL MARISCAL MARTINEZ Cetina L. et al.	CANCER TREAT REV	2003
164	Circulating nucleosomes and response to chemotherapy: An in vitro, in vivo and clinical study on cervical cancer patients	PATRICIA GARCIA LOPEZ MARCELA LIZANO SOBERON IGNACIO DANIEL MARISCAL MARTINEZ et al.	INTERNATIONAL JOURNAL OF CANCER	2003
165	Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma	ALFONSO DUEÑAS GONZALEZ AARON GONZALEZ ENCISO ALEJANDRO MOHAR BETANCOURT et al.	AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CA NCER CLINICAL TRIALS	2003
166	A Phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma	ALFONSO DUEÑAS GONZALEZ Cetina L. Sánchez B. et al.	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS	2003
167	Long-term results of paclitaxel in FIGO stage III ovarian carcinoma	ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ Gallardo-Rincón D. et al.	ANTI-CANCER DRUGS	2003
168	Neuroendocrine marker expression in cervical carcinomas of non-small cell type	ALFONSO DUEÑAS GONZALEZ Chavez-Blanco A. Taja-Chayeb L. et al.	INT J GYNECOL PATHOL	2002
169	Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: Results from two consecutive phase II studies	ALFONSO DUEÑAS GONZALEZ ALEJANDRO MOHAR BETANCOURT Lopez-Graniel C. et al.	ANNALS OF ONCOLOGY	2002
170	Correlation of tumor growth index with early treatment response in cervical carcinoma	ALFONSO DUEÑAS GONZALEZ Trejo-Becerril C. Rivera L. et al.	J EXP CLIN CANC RES	2002

ALFONSO DUEÑAS GONZALEZ

171	Type III radical hysterectomy induction chemotherapy for patients with locally advanced cervical carcinoma (multiple letters)	ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ Lopez-Graniel C. et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2002
172	A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma: Preliminary report	ALFONSO DUEÑAS GONZALEZ Verastegui E. Lopez-Graniel C. et al.	INTERNATIONAL IMMUNOPHARMACOLOGY	2002
173	The advantages of concurrent chemoradiation after neoadjuvant chemotherapy for locally advanced cervical carcinoma	ALFONSO DUEÑAS GONZALEZ AARON GONZALEZ ENCISO Rivera L. et al.	Archives Of Medical Research	2002
174	Cervical cancer. The case of Mexico	ALFONSO DUEÑAS GONZALEZ	CLINICAL & TRANSLATIONAL ONCOLOGY	2002
175	Neoadjuvant chemotherapy followed by surgery in locally advanced cervical carcinoma [4] (multiple letters)	ALFONSO DUEÑAS GONZALEZ ALEJANDRO MOHAR BETANCOURT Lopez-Graniel C.M. et al.	JOURNAL OF CLINICAL ONCOLOGY	2002
176	Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma	ALFONSO DUEÑAS GONZALEZ Hinojosa-García L.M. López-Graniel C. et al.	AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS	2001
177	Membrane proteins in neoplastic and normal uterine cervix	ALFONSO DUEÑAS GONZALEZ Trejo-Becerril C. Pérez-Cárdenas E. et al.	J EXP CLIN CANC RES	2001
178	Type III radical hysterectomy after induction chemotherapy for patients with locally advanced cervical carcinoma	ALEJANDRO MOHAR BETANCOURT ALFONSO DUEÑAS GONZALEZ Lopez-Graniel C. et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	2001
179	Cisplatin and vinorelbine in epithelial ovarian cancer in first line treatment. Pilot study [Cisplatino y vinorelbina en pacientes con cáncer de ovario epitelial como tratamiento de primera línea. Estudio piloto]	ALFONSO DUEÑAS GONZALEZ Ruíz G.C. Graniel C.M.L. et al.	CLINICAL & TRANSLATIONAL ONCOLOGY	2001
180	A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma	ALFONSO DUEÑAS GONZALEZ ALEJANDRO MOHAR BETANCOURT Lopez-Graniel C. et al.	ANNALS OF ONCOLOGY	2001

ALFONSO DUEÑAS GONZALEZ

181	Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglIII polymorphism of the p53 gene	ALFONSO DUEÑAS GONZALEZ Trejo-Becerril C. Sarmiento R.G. et al.	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS	2000
182	Neoadjuvant chemotherapy-interferon for epidermoid penile cancer. A case report	ALFONSO DUEÑAS GONZALEZ MARCELA LIZANO SOBERON JOSE LUIS AGUILAR PONCE et al.	Revista Del Instituto Nacional De Cancerología	1999
183	Adjuvant high-dose chemotherapy supported by peripheral blood stem cell transplantation for high-risk cervical carcinoma	ALFONSO DUEÑAS GONZALEZ Lara-Medina F.U. Solorza-Luna G. et al.	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	1999
184	The estrogen gen receptor in breast cancer. Friend or enemy? [El gen del receptor de estrogenos en el cancer de mama. Amigo o enemigo?]	ALFONSO DUEÑAS GONZALEZ	Revista Del Instituto Nacional De Cancerología	1999
185	Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: Therapeutic and pharmacoeconomic perspectives	ALFONSO DUEÑAS GONZALEZ JOSE LUIS AGUILAR PONCE Flores-Picazo Y. et al.	Archives Of Medical Research	1999
186	Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease	ALFONSO DUEÑAS GONZALEZ Isales C.M. Del Mar Abad-Hernandez M. et al.	MODERN PATHOLOGY	1997
187	Analysis of bcl-2 in sporadic breast carcinoma	ALFONSO DUEÑAS GONZALEZ Abad-Hernández M.D.M. Cruz-Hernández J.-J. et al.	CANCER	1997
188	Use of GM-CSF as prophylaxis of ganciclovir-induced-severe bone marrow suppression [Prevención de mielotoxicidad en un caso de trasplante medular con factor estimulante de colonias granulocito-macrófago asociado a ganciclovir]	ALFONSO DUEÑAS GONZALEZ Reynoso Gómez E. Miranda López E. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1996
189	Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study	ALFONSO DUEÑAS GONZALEZ Sobrevilla-Calvo P. Frias-Mendivil M. et al.	BONE MARROW TRANSPL	1996


ALFONSO DUEÑAS GONZALEZ

190	Higher sensitivity of the PCR-SSCP technique than the immunohistochemical technique for the detection of mutation in the exons 5 and 6 of the p53 gene in breast cancer [Mayor sensibilidad de la técnica de RCP-SSCP frente a la inmunohistoqu	ALFONSO DUEÑAS GONZALEZ Cruz Hernández J.J. Abad Hernández M.M. et al.	MEDICINA CLINICA	1996
191	Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings	ALFONSO DUEÑAS GONZALEZ Abad-Hernández M.M. García-Mata J. et al.	CANCER LETTERS	1996
192	Adult acute lymphoblastic leukemia. Experience at the Instituto Nacional de Cancerología, 1983-1987 [LEUCEMIA LINFOBLASTICA AGUDA DEL ADULTO. EXPERIENCIA DEL INSTITUTO NACIONAL DE CANCEROLOGIA DE 1983 A 1987]	ALFONSO DUEÑAS GONZALEZ Reynoso Gomez E.E. Andrade D. et al.	Revista Del Instituto Nacional De Cancerología	1994
193	Apoptosis and cancer [APOPTOSIS Y CANCER]	ALFONSO DUEÑAS GONZALEZ Cruz Hernandez J.J. Gonzalez Sarmiento R.	Revista Del Instituto Nacional De Cancerología	1994
194	Drug repurposing for cancer therapy, easier said than done	ALFONSO DUEÑAS GONZALEZ Gonzalez-Fierro A.	SEMINARS IN CANCER BIOLOGY	

ALFONSO DUEÑAS GONZALEZ

LIBROS Y CAPITULOS CON ISBN

Obras con registro ISBN



#	Título	Autores	Alcance	Año	ISBN
1	El cáncer del cáncer	ALFONSO DUEÑAS GONZALEZ	Libro Completo	2023	9786072942325
2	Introduction of Epigenetic Targets in Drug Discovery and Current Status of Epi-Drugs and Epi-Probes	ALFONSO DUEÑAS GONZALEZ JOSE LUIS MEDINA FRANCO Jesús Naveja J.	Capítulo de un Libro	2016	9780128028094
3	Drug Repurposing for Epigenetic Targets Guided by Computational Methods	ALFONSO DUEÑAS GONZALEZ JOSE LUIS MEDINA FRANCO Jesús Naveja J.	Capítulo de un Libro	2016	9780128028094
4	DNA Methyltransferase Inhibitors for Cancer Therapy	JOSE LUIS MEDINA FRANCO ALFONSO DUEÑAS GONZALEZ Yoo J.	Capítulo de un Libro	2015	9780128013274
5	In Vivo Rat Model to Study Horizontal Tumor Progression	ALFONSO DUEÑAS GONZALEZ	Capítulo de un Libro	2014	9781493908554
6	Epigenetics of cancer	ALFONSO DUEÑAS GONZALEZ García-cuellar C.M.	Capítulo de un Libro	2012	9781608056118
7	Conociendo al enemigo: El cáncer	ALFONSO DUEÑAS GONZALEZ	Libro Completo	2010	9786070218002



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



ALFONSO DUEÑAS GONZALEZ

PARTICIPACIÓN EN PROYECTOS


No se encuentran registros en la base de datos de SISEPRO asociados a:

ALFONSO DUEÑAS GONZALEZ

ALFONSO DUEÑAS GONZALEZ

PARTICIPACIÓN EN TESIS

Histórico de Colaboraciones en Tesis



#	Título del documento	Tipo de Tesis	Sinodales	Autores	Entidad	Año
1	Caracterización de proteínas asociadas al DNA en circulación y la participación de estas proteínas en la transformación celular	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	JUAN PABLO REYES GRAJEDA, Cruz Sigüenza, Desiree Ariadna de la,	Facultad de Medicina, Instituto de Investigaciones Biomédicas,	2024
2	Reposicionamiento terapéutico en cáncer de colon : uso de la DNasa I en un modelo in vitro e in vivo	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Bermúdez Esquivel, Corina Guadalupe,	Instituto de Investigaciones Biomédicas,	2022
3	Evaluación de la ivermectina como agente anti-tumoral	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	Juárez Rodríguez, Mandy,	Instituto de Investigaciones Biomédicas,	2020
4	Efecto de la combinación de hidralazina y valproato de magnesio y su comparación con vorinostat y decitabina en una línea celular de linfoma cutáneo de células T	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Santamaría Jiménez, Beatriz,	Instituto de Investigaciones Biomédicas,	2019

ALFONSO DUEÑAS GONZALEZ

5	Evaluación de narasina e ivermectina como inhibidores de la viabilidad de células troncales de cáncer de mama	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Flores Torrontegui, Ytzel,	Instituto de Investigaciones Biomédicas,	2019
6	Potencial participación del DNA circulante en el proceso de carcinogénesis	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Cobos Uribe, Catalina,	Instituto de Investigaciones Biomédicas,	2017
7	Evaluación del efecto antitumoral de la combinación de hidralazina y valproato en líneas celulares de linfoma	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Salamanca Ortiz, Harold Andrés,	Instituto de Investigaciones Biomédicas,	2017
8	Reposicionamiento farmacéutico del ribavirín en linfomas no Hodgkin	Tesis de Licenciatura	ALFONSO DUEÑAS GONZALEZ,	Cortés Pedroza, Dominique,	Instituto de Investigaciones Biomédicas,	2017
9	Estudio preclínico del tratamiento sistémico con proteasas y dnasa en dos modelos tumorales in vivo	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	González Ballesteros, Mauricio Misael,	Instituto de Investigaciones Biomédicas,	2016
10	Estudio preclínico de la dnasa I y proteasas como estrategia antitumoral : ensayo preliminar	Tesis de Licenciatura	ALFONSO DUEÑAS GONZALEZ,	Gutiérrez Díaz, Blanca Teresa,	Instituto de Investigaciones Biomédicas,	2016
11	El DNA libre en circulación y su papel en la transformación celular	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	Trejo Becerril, Catalina,	Instituto de Investigaciones Biomédicas,	2014
12	Cambios epigenéticos de los genes implicados en el transporte y activación del antimetabolito gemcitabina, como mecanismo de resistencia en cáncer cervicouterino	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	Candelaria Hernández, Myrna Gloria,	Instituto de Investigaciones Biomédicas,	2012
13	La desmetilación del satélite 2 se asocia con la presencia de errores en la segregación de los cromosomas 1 y 16 en células somáticas adultas	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	LUIS ALONSO HERRERA MONTALVO, FABIO ABDEL SALAMANCA GOMEZ, et al.	Facultad de Medicina, Instituto de Investigaciones Biomédicas,	2011

ALFONSO DUEÑAS GONZALEZ

14	Virus de papiloma humano y polimorfismos del gen TP53 en cáncer cervical uterino	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	Piña Sánchez, Patricia,	Instituto de Investigaciones Biomédicas,	2010
15	Posible participación de los fibrocitos en la expansión tisular de fibroblastos en fibrosis pulmonar idiopática	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	ANNIE PARDO CEMO, García de Alba Rivas, Carolina,	Facultad de Ciencias, Instituto de Investigaciones Biomédicas,	2010
16	Evaluación del compuesto LQM502 como desmetilante del ADN y reactivador de la expresión de genes supresores de tumores en cáncer	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Camargo García, María Fernanda,	Instituto de Investigaciones Biomédicas,	2008
17	Expresión de marcadores neuroendocrinos en cáncer cervicouterino de células no pequeñas	Tesis de Especialidad	ALFONSO DUEÑAS GONZALEZ,	Cetina Perez, Lucely del Carmen,		2007
18	Expresión de los receptores de PDGF y sus ligandos en cáncer cervicouterino : implicaciones para el uso terapéutico de mesilato de imatinib	Tesis de Especialidad	ALFONSO DUEÑAS GONZALEZ,	Martínez Tlahuel, Jorge Luis,		2006
19	Análisis mutacional de los genes EGFR y PDGFR en cáncer de pulmón y cervicouterino	Tesis de Doctorado	ALFONSO DUEÑAS GONZALEZ,	Taja Chayeb, Lucía Guadalupe,		2006
20	Efecto del gen E6 del virus del papiloma humano 18 (VPH) y hormonas esteroideas sobre el factor de crecimiento de endotelio vascular (VEGF) en la línea celular MCF7	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	MARCELA LIZANO SOBERON, Cantu de León, David Francisco,		2005


ALFONSO DUEÑAS GONZALEZ

21	Busqueda de secuencias oncogenicas en DNA extracelular de lineas celulares de cancer, metastasicas y no metastasicas	Tesis de Licenciatura	ALFONSO DUEÑAS GONZALEZ,	Vanoye Carlo, America,	2004
22	Inhibicion de la metilacion del gen de receptor a estrogénos y genes supresores p 16 y Rb en lineas de cancer de mama	Tesis de Maestría	ALFONSO DUEÑAS GONZALEZ,	Segura Pacheco, Blanca Angélica,	2004
23	Metilacion de genes supresores de tumor en pacientes con cancer cervicouterino	Tesis de Especialidad	ALFONSO DUEÑAS GONZALEZ,	Mariscal Ramirez, Ignacio,	2003
24	La apoptosis en cancer cervico uterino	Tesis de Especialidad	ALFONSO DUEÑAS GONZALEZ,	Rivera Rubi, Lesbia Maria,	2003
25	Efectos del estradiol y de un antiestrogeno puro en la proliferacion de lineas celulares de cancer cervico uterino	Tesis de Licenciatura	ALFONSO DUEÑAS GONZALEZ,	Maycotte Gonzalez, Paola,	2002
26	Estudio fase I de carboplatino semanal concomitante con radioterapia en carcinoma de cervix en estadio III-B	Tesis de Especialidad	ALFONSO DUEÑAS GONZALEZ,	Sanchez Llamas, Benito,	2002

ALFONSO DUEÑAS GONZALEZ

DOCENCIA IMPARTIDA

Histórico de docencia



#	Nivel titulación	Asignatura	Entidad	Alumnos	Semestre
1	Maestría	SEMINARIO DE INVESTIGACIÓN I	Facultad de Química	1	2024-1
2	Maestría	TRABAJO DE INVESTIGACIÓN I	Facultad de Química	1	2024-1
3	Maestría	SEMINARIO DE INVESTIGACIÓN III	Facultad de Química	1	2022-1
4	Maestría	SEMINARIO DE INVESTIGACIÓN III	Facultad de Química	1	2022-1
5	Maestría	TRABAJO DE INVESTIGACIÓN III	Facultad de Química	1	2022-1
6	Maestría	TRABAJO DE INVESTIGACIÓN III	Facultad de Química	1	2022-1
7	Maestría	SEMINARIO DE INVESTIGACIÓN II	Facultad de Química	1	2021-2
8	Maestría	SEMINARIO DE INVESTIGACIÓN II	Facultad de Química	1	2021-2
9	Maestría	TRABAJO DE INVESTIGACIÓN II	Facultad de Química	1	2021-2
10	Maestría	TRABAJO DE INVESTIGACIÓN II	Facultad de Química	1	2021-2
11	Maestría	SEMINARIO DE INVESTIGACIÓN I	Facultad de Química	1	2021-1
12	Maestría	SEMINARIO DE INVESTIGACIÓN I	Facultad de Química	1	2021-1
13	Maestría	TRABAJO DE INVESTIGACIÓN I	Facultad de Química	1	2021-1
14	Maestría	TRABAJO DE INVESTIGACIÓN I	Facultad de Química	1	2021-1
15	Maestría	CURSO III	Facultad de Química	1	2020-1
16	Maestría	SEMINARIO DE INVESTIGACIÓN III	Facultad de Química	2	2020-1
17	Maestría	TRABAJO DE INVESTIGACIÓN III	Facultad de Química	1	2020-1
18	Maestría	TRABAJO DE INVESTIGACIÓN III	Facultad de Química	1	2020-1
19	Maestría	SEMINARIO DE INVESTIGACIÓN II	Facultad de Química	2	2019-2
20	Maestría	TRABAJO DE INVESTIGACIÓN II	Facultad de Química	1	2019-2
21	Maestría	TRABAJO DE INVESTIGACIÓN II	Facultad de Química	1	2019-2
22	Doctorado	ESTANCIA CLINICA I	Facultad de Medicina	1	2019-2
23	Doctorado	TUTORIA IV	Facultad de Medicina	1	2019-2

ALFONSO DUEÑAS GONZALEZ

24	Maestría	SEMINARIO DE INVESTIGACIÓN I	Facultad de Química	2	2019-1
25	Maestría	TRABAJO DE INVESTIGACIÓN I	Facultad de Química	2	2019-1
26	Maestría	SEMINARIO DE INVESTIGACION III	Facultad de Química	2	2018-2
27	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2018-2
28	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2018-2
29	Maestría	TRABAJO DE INVESTIGACION IV	Facultad de Ciencias	1	2018-2
30	Maestría	SEMINARIO DE INVESTIGACION II	Facultad de Química	2	2018-1
31	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2018-1
32	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2018-1
33	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Ciencias	1	2018-1
34	Maestría	TRABAJO DE INVESTIGACIÓN II	Facultad de Ciencias	1	2017-2
35	Maestría	TRABAJO DE INVESTIGACIÓN I	Facultad de Química	2	2017-2
36	Maestría	SEMINARIO DE INVESTIGACIÓN I	Facultad de Química	2	2017-2
37	Maestría	SEMINARIO DE INVESTIGACIÓN III	Facultad de Química	1	2017-2
38	Maestría	TRABAJO DE INVESTIGACIÓN III	Facultad de Química	1	2017-2
39	Doctorado	EL PARADIGMA DEL CÁNCER. SITUACIÓN ACTUAL Y NUEVAS PRESPECTIVAS SOBRE LA ENFERMEDAD	Instituto de Investigaciones Biomédicas	10	2017-2
40	Maestría	TRABAJO DE INVESTIGACION I-393804	Facultad de Ciencias	1	2017-1
41	Maestría	SEMINARIO DE INVESTIGACION II-313275	Facultad de Química	1	2017-1
42	Maestría	TRABAJO DE INVESTIGACION II-313359	Facultad de Química	1	2017-1
43	Maestría	TRABAJO DE INVESTIGACION III-313601	Facultad de Química	1	2017-1
44	Licenciatura	TRABAJO DE INVESTIGACION 8	Facultad de Medicina	1	2016-2
45	Licenciatura	TRABAJO DE INVESTIGACION 4	Facultad de Medicina	1	2016-2
46	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Química	1	2016-2
47	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2016-2
48	Doctorado	SERVICIO SOCIAL EN INVESTIGACION	Facultad de Medicina	1	2016-2
49	Maestría	SEMINARIO DE INVESTIGACION I	Facultad de Química	1	2016-2
50	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2016-1
51	Maestría	SEMINARIO DE INVESTIGACION III	Facultad de Química	1	2016-1
52	Licenciatura	TRABAJO DE INVESTIGACION 7	Facultad de Medicina	1	2016-1
53	Licenciatura	TRABAJO DE INVESTIGACION 3	Facultad de Medicina	1	2016-1
54	Maestría	CURSO IV	Facultad de Química	1	2015-2
55	Maestría	SEMINARIO DE INVESTIGACION III	Facultad de Química	1	2015-2
56	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2015-2
57	Maestría	SEMINARIO DE INVESTIGACION II	Facultad de Química	1	2015-2
58	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2015-2
59	Licenciatura	TRABAJO DE INVESTIGACION 6	Facultad de Medicina	1	2015-2
60	Licenciatura	TRABAJO DE INVESTIGACION 8	Facultad de Medicina	1	2015-1
61	Licenciatura	TRABAJO DE INVESTIGACION 5	Facultad de Medicina	1	2015-1
62	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2015-1
63	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Química	1	2015-1
64	Maestría	SEMINARIO DE INVESTIGACION II	Facultad de Química	1	2015-1

ALFONSO DUEÑAS GONZALEZ

65	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2015-1
66	Maestría	SEMINARIO DE INVESTIGACION III	Facultad de Química	1	2015-1
67	Maestría	SEMINARIO DE INVESTIGACION I	Facultad de Química	1	2015-1
68	Maestría	SEMINARIO DE INVESTIGACION I	Facultad de Química	1	2014-2
69	Maestría	SEMINARIO DE INVESTIGACION II	Facultad de Química	1	2014-2
70	Licenciatura	TRABAJO DE INVESTIGACION 7	Facultad de Medicina	1	2014-2
71	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Química	1	2014-2
72	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Química	1	2014-2
73	Doctorado	ACTIVIDAD ACADEMICA OPTATIVA	Facultad de Medicina	1	2014-2
74	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Química	1	2014-1
75	Maestría	SEMINARIO DE INVESTIGACION I	Facultad de Química	1	2014-1
76	Maestría	SEMINARIO DE INVESTIGACION III	Facultad de Química	1	2013-2
77	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Química	1	2013-2
78	Licenciatura	TRABAJO DE INVESTIGACION 4	Facultad de Medicina	1	2012-2
79	Licenciatura	TRABAJO DE INVESTIGACION 3	Facultad de Medicina	1	2012-1
80	Maestría	TRABAJO DE INVESTIGACION IV	Facultad de Medicina	2	2009-1
81	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Medicina	2	2008-2
82	Licenciatura	TRABAJO DE INVESTIGACION 6	Facultad de Medicina	1	2008-2
83	Licenciatura	TRABAJO DE INVESTIGACION 5	Facultad de Medicina	1	2008-1
84	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Medicina	2	2008-1



ALFONSO DUEÑAS GONZALEZ

PATENTES

#	Título	Inventores	Sección	Año
1	USO DE AGENTES MODIFICANTES DEL TRANSCRIPTOMA MAS QUIMIOTERAPIA O RADIOTERAPIA CONTRA EL CANCER.	ALFONSO DUEÑAS GONZALEZ,	CHEMISTRY; METALLURGYHUMAN NECESSITIES	2012
2	COMPUESTOS ANALOGOS DEL ESTER FENETILICO DEL ACIDO CAFEICO Y USO DE LOS MISMOS PARA PREPARACION DE COMPOSICIONES FARMACEUTICAS PARA PREVENCIÓN Y TRATAMIENTO DE CANCER.	ANA MARIA VELAZQUEZ SANCHEZ, ENRIQUE RAMON ANGELES ANGUIANO, SANDRA DIAZ BARRIGA ARCEO, et al.	CHEMISTRY; METALLURGYHUMAN NECESSITIES	2018

ALFONSO DUEÑAS GONZALEZ

FUENTES DE INFORMACIÓN

Internos

#	Información	Fuente	Sistema	Periodo
1	Grupos ordinarios y resumen de historias académicas	DGAE	SIAE	2008-2025
2	Nombramientos, datos generales, estímulos, premios y reconocimientos	DGAPA	RUPA	2008-2025
3	Producción Académica	CH	Humanindex	2008-2021
4	Producción Académica	CIC	SCIC	2000-2017
5	Proyectos	DGPO	SISEPRO	2018-2022
6	Tesis	DGB	TESIUNAM	2008-2025
7	Tutorías en Posgrado	CGEP	SIIPosgrado	2008-2021

Externos

#	Información	Fuente	Sistema	Periodo
8	Documentos Indexados	Elsevier	Scopus	2008-2025
9	Documentos Indexados	Thomson Reuters	WoS	2008-2025
10	Obras con registro ISBN	INDAUTOR	Agencia ISBN	2008-2025
11	Patentes	IMPI	SIGA	2008-2024